Altimmune, Inc. (ALT) Tops Q4 EPS by 1c

Altimmune, Inc. (NASDAQ: ALT) reported Q4 EPS of ($0.33), $0.01 better than the analyst estimate of ($0.34).

For earnings history and earnings-related data on Altimmune, Inc. (ALT) click here.

You May Also Be Interested In

• Karyopharm Therapeutics (KPTI) Misses Q2 EPS by $1.01, Beats on Revenue; Offers FY26 Revenue Guidance
• CorMedix (CRMD) Tops Q2 EPS by 6c; Offers Guidance
• ADC Therapeutics SA (ADCT) Tops Q2 EPS by 11c